© Copyright Nostre Net
Market Highlights
Facial paralysis is a restriction of the facial movement due to nerve damage. Facial nerve paralysis is characterized by unilateral facial weakness. Some other symptoms include loss of taste, hyperacusis, and decreased salivation and tear secretion.
Asia Pacific is the fastest growing market for facial paralysis whose growth is attributed to the rising population and increasing standard of living. Additionally, the increasing healthcare spending and the improved standard of living are likely to drive the growth of the market. India and China are the major contributors to the market growth due to the rapid development of healthcare infrastructure in these regions and the increasing demand for diagnostic services.
The global facial paralysis market is expected to register a CAGR of 6.5% during the forecast period.
Key Players
Some of the key players in the facial paralysis market are, Boston Scientific, BioControl Medical, Cerebomed, Cyberonics, Astellas Pharma Inc., Sucampo Pharmaceuticals, Inc., and Novartis AG, among others.
On the other hand, the Middle East and Africa is expected to witness a gentle growth due to limited access to the healthcare industry and affordability issues among the population. In the Middle East, the growth of the market is driven by the increasing availability of new and advanced diagnostic and treatment methods for various chronic diseases.
Segmentation
The global facial paralysis market is segmented on the basis of treatment, diagnosis, type, and end-user.
On the basis of type, the market is segmented into, Ramsay Hunt Syndrome, facial erythema, Bell’s Palsy, and Lyme Disease.
On the basis of diagnosis, the market is segmented into electromyography, computerized tomography, and magnetic resonance imaging.
On the basis of treatment, the market is segmented into medications, physical therapy, and surgery.
On the basis of medication, the market is further sub-segmented into corticosteroids and antiviral drugs.
On the basis of end-user, the market is segmented into hospitals and clinics, specialty centers, and research centers.
Regional Analysis
The Americas dominates the global facial paralysis market owing to increasing cardiovascular disorders, which eventually leads to the increasing patient population. Additionally, increasing cardiovascular disorder rate is likely to enhance the growth of facial paralysis in the North American region. According to the American Heart Association, 31% of the deaths in the U.S. were due to cardiovascular disorders. Similarly, in 2015, around USD 3.2 trillion were spend in healthcare expenditure in the U.S according to the Center for Disease Control and Prevention. Similarly, in 2015, 1.3% of the U.S. adults were diagnosed with inflammation of facial nerves.
Europe accounts for the second largest market due to increasing cardiovascular disorders and increasing infections. Additionally, the increasing government support and improving healthcare infrastructure along with increasing facial inflammations are driving the growth of the facial paralysis market in Europe. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. This increasing older population is likely to lead to the increasing patient population. These factors are likely to drive the growth of the facial paralysis market.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Overview:
The gout market is anticipated to reach USD 4162.5 Million by 2030 at 11.75% CAGR during the forecast period 2022-2030, which has been marked as the forecast period by Market Research Future (MRFR) in the published report. The report also includes several factors that can make sure the market would grow in the coming years. Gout can be described as a type of arthritis, which is caused by higher uric acid levels in the blood. The disease can be triggered by high blood pressure, high cholesterol, and medications that can spike the presence of uric acid in the blood. Obesity, diet containing a high amount of red meat, consumption of alcohol and smoking can trigger symptoms of gout.
The market is getting better thrust from factors like growing elderly population, transforming lifestyle that includes more sedentary time, advents of better treatment facilities, and government initiatives. However, lack of awareness can make this growth daunting in the coming years.
Competitive Landscape:
The gout market is having a strong influx of various new players who are giving tough competition to the existing market bigshots. These players are launching their own types of market strategies to make sure that they get good mileage from the market. Their strategic moves often include mergers, new launches, acquisitions, investment, and others. MRFR got these changes recorded in the report to get a closer view of how the market is shaping up. These players are Savient Pharmaceuticals, Takeda Pharmaceutical Company Ltd. Merck & Co. Inc., AstraZeneca plc, Astellas Pharma Inc., Ardelyx, Inc., and Novartis AG.
Segmentation:
The global gout market, as the reports of MRFR suggests, can be studied on the basis of an expert segmentation that includes end-user, treatment, type, and diagnosis. The report focuses on achieving insights from the market and that has initiated a detailed review of each segment.
By type, the report on the gout market can be segmented into tophaceous gout and pseudogout. Both these segments are known for their impact on the market and revenue-generation.
By treatment, the gout market report can be segmented into medications and self-care. The medication segment includes Probenecid, Allopurinol, Febuxostat, Diclofenac, Indomethacin, and Ibuprofen. The self-care segment is getting acknowledged by patients across the world.
By diagnosis, the market report on the gout industry can be segmented into blood tests, MRI, X-ray, ultrasound, urine test, CT scan, and others. Growing demand for early diagnosis is expected to set up a significant scope for these tests to fetch high income.
By the end-user, the market report on the gout industry comprises specialty centers, hospitals, and homecare. The home care segment is witnessing a surge as an increasing number of people are opting for the self-care segment.
Regional Analysis:
The North American gout market has a notable chance of making progress in the coming years. The regional market is known for its high expenditure for the research and development sector, which is triggering an increasing number of medicines that are getting launched every year. Major countries inspiring changes are the US and Canada. The regional number of smokers is also quite high, which, along with the high number of geriatric population, can trigger the expansion of the gout market. High number of obese people can also open up spaces for such diseases.
Europe’s market is the second-highest as the regional awareness regarding gout-related problems is quite high. This is getting fostered by the rising number of elderly people. Advanced treatment facilities are also getting introduced owing to which a lot of people are showing interest in getting their disease healed. This is also getting bolstered by a rising amount of investment.
The Asia Pacific market is going to show changes in the market as the growing awareness and the massive population is expected to transform the market dynamics. The demographic conditions are also going to play in favor of the market. Countries are launching extensive plans for their healthcare sectors that can influence the gout market growth as well. China would be the fastest-growing country. Transforming lifestyles are also going to create space for market expansion.
The Middle East & Africa market may suffer from the presence of poor economies, lack of awareness, and insufficient backing from the technological setup. However, the scenario is changing in countries like the UAE, Dubai, Saudi Arabia, Qatar, and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Mental health has come into focus due to changing lifestyles of patients and unhealthy work hours. Mental health software and devices utilizes the power of information technology to keep a check on mental or behavioral disorders. The global mental health software and devices market report by Market Research Future (MRFR) focuses on various issues plaguing the market as well as efforts by manufacturers.
The mental health software and devices market is expected to reach USD 17.2 Billion by 2030 at 16.1% CAGR during the forecast period 2022-2030
Market Outlook
due to the rapid adoption of software by mental health professionals. Change in health practices due to availability of patient records and mental health history can lead to effective management of patients. Collection and analysis of information, elimination of errors, rise in patient income levels, and demand for effective solutions for management of pharmacies are mental health are other drivers of the market.
Competition Outlook
Prominent mental health software vendors and device manufacturers profiled in the report include Athena Health, Mindlinc, Mentegram, WRS Health, Kareo, Nextgen Healthcare, ICANotes, Core Solutions, InSync Healthcare Solutions, Compulink, Allscripts, Nuesoft Technologies, NextStep Solutions, Valant, Credible Behavioral Health, Welligent, Raintree Systems, Netsmart, Meditab Software, Orion Health, The Echo Group, Sigmund Software, IBM, TheraNest, Advanced Data Systems, AdvancedMD, Qualifacts, McKesson Corporation, iSalus Healthcare, and Cerner Corporation.
Segmentation Analysis
the global mental health software and devices market is segmented on the basis of solution, deployment, end users and regions.
By component, the market has been segmented by software and devices. The software has been sub-segmented into web based and standalone software.
By functionality, the market has been segmented by clinical, administrative, financial and others. The clinical segment has been categorized into tele-health, electronic health records (EHRs), E-prescribing, clinical decision support, health management, and others. The administrative has been sub segmented into information management, scheduling, workforce management, and others.
The financial has been sub segmented into accounting, revenue cycle management, business intelligence, and others.
Regional Analysis
Region-wise, the global market comprises North America, Middle East & Africa (MEA), Asia Pacific (APAC), and Europe.
North America accounted for the largest market led by the U.S. due to focus on mental health by governments. According to the American Psychological Association in 2019, the number of young U.S. citizens with an increase of mental health disorders has risen due to shift in mood disorders. Other drivers include rapid adoption of technology and development of healthcare infrastructure by governments.
Europe is the second largest region of the market driven by large number of burnout cases and mental health issues of employees. Governments in the region have developed a common platform for collection of mental health issues and records of patients for implementation of good policies as well as welfare schemes. On the other hand, the APAC region is expected to exhibit the fastest growth rate during the forecast period due to being driven by economies of China, India, and Japan. International brands in the region are giving mental health insurance for preventing burnouts and reducing stress in the workplace.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Surgical devices are types of instruments that are used for performing numerous forms of surgeries in accordance to the complexity of the surgery like minimally invasive, open, or other types of surgery. The General Surgical Devices Market is anticipated to reach USD 15.1 Billion by 2030 at 8.60% CAGR during the forecast period 2022-2030.
As per the research conducted by Market Research Future (MRFR), the market is identified to be influenced by numerous factors. The high demand centered around disposable supplies like catheters, syringes, and needles, the growing awareness concerning diseases being transmitted through surgical forms of devices, and favorable government regulations in ensuring or maintaining safety in surgical procedures are expected to stimulate a positive demand for disposable products, thereby pushing the overall general surgical devices market. An influx of global health initiatives causing advancement in surgical procedures are expected to drive the global general surgical devices market. However, factors like strict government regulations in developing nations and improper reimbursement for surgical devices can cause the market to falter in terms of growth.
Competitive Landscape
The global general surgical devices market comprises of numerous players. A few of them identified in the report are 3M Healthcare (U.S.), Johnson & Johnson Services, Inc. (U.S.), B. Braun Melsungen AG (Germany), Grifols (Spain), SOFINA s.a (Biomérieux) (U.S.), Erbe Elektromedizin GmbH (Germany), Integra LifeSciences (U.S.), Medtronic Plc. (U.S.), Smith & Nephew (U.S.), Stryker Corporation (U.S.), Maquet Holding B.V. & CO. KG. (Germany), CareFusion Corporation (U.S.), Becton, Dickinson and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Conmed Corporation (U.S.), Accuray Incorporated (U.S), Boston Scientific Corporation (U.S.), Ortho-Clinical Diagnostics, Inc. (U.S.), Intuitive Surgical Inc. (U.S.), Siemens Healthcare GmbH (Germany), Cadence Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Virtual Incision Corporation (U.S.), Titan Medical (Canada), Medrobotics Corporation (U.S.), TransEnterix Surgical (U.S.), Olympus Corporations (U.S.), Verb Surgical (U.S.), Meere Company (U.S.), and others.
Market Segmentation
The global general surgical devices market segmentation is done on the basis of application, type, product, and end-user.
By type, the market includes energy-based and powered instrument, disposable surgical supplies, minimally invasive surgery instruments, surgical instruments, medical robotics, open surgery instrument, computer-assisted surgery devices, and others.
By product, the market includes electrosurgical devices, trocars and access devices, handheld devices, wound closure devices, laparoscopic devices, and others.
By application, the market comprises thoracic surgery, ophthalmology, plastic surgery, orthopedic surgery, cardiology, neurosurgery, audiology, into wound care, urology and gynecology surgery, and others.
By end-user, the market includes research centers, diagnostic centers, hospitals, academic institutes, clinics, and others.
Regional Analysis
The global general surgical devices market is geographically segmented across the following regions: Europe, America, Asia Pacific, and the Middle East and Africa.
The Americas dominate the global market with the highest share percentage and is expected to further maintain its standings in the forthcoming years. This is due to the vast presence of key players, a striking number of surgical procedures, favorable reimbursement policies, and various initiatives undertaken by the government for providing training sessions as well as access to advanced devices for physicians.
The Asia Pacific region is projected to grow at the maximum pace during the forecast period owing to growing investments alongside the regional expansion. The Middle East and Africa region boasts the potential to emerge out as a big production hub for large-scale development and medical devices. This is due to the low cost associated with product development here in this region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Insights
The non-invasive nature of optical coherence tomography (OCT) and its ability to generate a false-color depiction of tissue structure has made the global market for OCT highly lucrative. OCT is comparable to ultrasound imaging, with the principal difference that the technology uses light instead of sound. Research & development of the technology has led to efficient, fast and accurate OCT devices which have branched out from ophthalmology to include medical applications in dermatology, and cardiology among others, thus facilitating growth. Market Research Future's report on the Optical Coherence Tomography Market to gain a valuation of USD 15.50 Billion by 2030 at 15.5% CAGR.
Prevalence of eye diseases and the rising occurrence of cardiac conditions have motivated market growth. Rising demand for OCT has led to R&D for technological advancements which in turn is expected to increase market growth further. Presently, although there are many applications for OCT devices, they are primarily used in ophthalmology, this indicates unrealized potential yet to be explored which will likely push demand for this technology in the coming years.
High costs associated with portable optical coherence tomography may hamper growth. However, increasing use in various applications, supportive government regulations and favorable reimbursements are likely to mitigate this challenge to a great extent.
Market Segmentation
The optical coherence tomography market has been segmented by technology, application, type of devices and region.
By technology, the market has been segmented into spectral-domain OCT (SD-OCT), swept-source OCT, and others. The SD-OCT segment is predicted to dominate with approximately 60% share of the total market during the forecast period. Meanwhile, swept-source OCT is the fastest growing segmented and is expected to grow at CAGR of 9.1% during the review period.
By application, the market has been segmented into cardiology, ophthalmology, dermatology, oncology, and others. Ophthalmology has the most significant segment with over 53% of the market share. However, dermatology is the fastest growing application segment and is expected to grow at a considerable 9.3% CAGR during the forecast period.
By type of devices, the market has been segmented into handheld OCT devices, tabletop OCT devices, catheter-based OCT devices, and others.
By region, the market has been segmented into the Americas, Europe, Asia Pacific and the Middle East and Africa.
Regional Analysis
The Americas hold the largest share with nearly 37% of the global market share. Increasing occurrence of diabetic retinopathy and other eye diseases is one of the key factors driving the growth of the market. Moreover, there is a strong presence of market leaders. MRFR as predicted that region will reach an evaluation of approximately USD 558.34 million by 2023.
Europe follows the Americas lead and is expected to maintain a strong second lead due to supportive government policies and research & development carried out by private players is the primary propeller for the growth of the OCT market over the forecast period. The region is expected to closely follow the growth pattern of the Americas.
The Asia-Pacific region, is predicted to be the fastest growing region with a CAGR of 9.4% during the forecast period. A massive patient population in the region with a rising incidence of eye diseases and diabetic retinopathy is expected to fuel rapid growth for the region. International market leaders are trying to enter this region, and this is likely to facilitate growth in the coming years further.
The Middle East & Africa are expected to experience limited growth. This is primarily due to the passive development in the African continent.
Key Players
Market leaders have been featured in the report to provide a comprehensive understanding of the competitive landscape. Prominent players included in the report are Imalux Corporation, Optovue, Michelson Diagnostics, Carl Zeiss AG, Alcon, Abbott Laboratories, Terumo Corporation, KONINKLIJKE PHILIPS N.V, B. Braun Melsungen AG, Boston Scientific Corporation, OPTOPOL Technology S.A, Heidelberg Engineering GmbH, Topcon Corporation, NIDEK Co., Ltd, Novacam Technologies Inc, Thorlabs Inc., and Agfa Healthcare
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Synopsis
Vaccines administered to children to prevent them from several infectious and non-infectious diseases are referred to as pediatric vaccines. They are either heat-killed or inactivated viruses which lose their pathogenicity. These inactivated antigens stimulate the immune system so that they can produce antibodies against the infected virus. The pediatric vaccines market is expected to reach USD 35.52 Billion by 2030 at 9.90% CAGR during the forecast period 2022-2030.
Potential and Pitfalls
Various pediatric vaccines available in the market are hepatitis B antibody, flu immunization, meningococcal immunization, pneumococcal immunization, rotavirus immunization, Hib antibody, polio antibody, and MMR immunization. With growing economic growth, rising awareness associated with the benefits of vaccination in prevention of diseases, and favorable reimbursement, the global market for pediatric vaccine is anticipated to flourish during the estimated period. The growing collaboration of local manufacturers with the major market players to deliver high-quality vaccines in the remote areas are further considered to foster the market growth in the coming years. Moreover, high prevalence of chronic diseases is one of the key factors boosting the global market. Infants are more prone to severe diseases, and therefore vaccination plays an important role in their prevention.
Competitive Dashboard
The major players operating the global pediatric vaccines market are Zydus Cadila (India), S K Chemicals (South Korea), AstraZeneca (UK), Bio Med (India), Sanofi Pasteur SA (France), Bharat Biotech (India), Shenzhen Kangtai Biological Products (China), Sinovac Biotech (China), Pfizer Inc. (U.S.), Nuron (U.S.), CSL Limited (Australia), Merck & Co. Inc. (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Protein Sciences Corporation (U.S.), Dynavax Technologies (U.S.), LG Life Sciences (India), Kaketsuken (U.S.), Emergent BioSolutions Inc. (U.S.), Crucell (Netherlands), GlaxoSmithKline plc (U.K.), Grifols (Spain), Bharat Immunologicals and Biologicals (India), Lupin Pharmaceuticals, Inc. (India), Panacea Biotec (India), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Novartis AG (Switerzland), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), bioCSL Inc. (U.S.), Takeda Pharmaceutical (Japan), MedImmune LLC (U.S.), Indian Immunologicals (India), Baxter International (U.S.), Valeant Pharmaceuticals (U.S.) and others.
Global Pediatric Vaccines Market: Segmental Analysis
The global pediatric vaccines market has been segmented on the basis of technology, type, route of administration, disease indication, and region.
By mode of type, the global pediatric vaccines market is segmented into multivalent vaccines, monovalent vaccines, and others.
By mode of technology, the global pediatric vaccines market is segmented into conjugate vaccines, dendritic cells vaccines, pediatric mobility devices, recombinant vaccines, inactivated and subunit vaccines, live attenuated vaccines, synthetic vaccines, toxoid vaccines, and others. Among these, the conjugate vaccines segment is likely to dominate the market owing to the increasing prevalence of meningococcal and pneumococcal infections.
By mode of disease indication, the global pediatric vaccines market is segmented into hepatitis, meningococcal disease, MMR (measles, mumps, and rubella), rotavirus, polio, combination vaccines, varicella, pneumococcal disease, haemophilus influenza type B, influenza, DTP (diphtheria, tetanus, pertussis), and others.
By mode of route of administration, the global pediatric vaccines market is segmented into subcutaneous administration, intramuscular administration, oral administration, and others.
Regional Insights
Geographically, the pediatric vaccines market span across regions namely, Europe, America, the Middle East and Africa, and the Asia Pacific region.
Among all the regions, America is considered to hold the largest market share and is likely to maintain its dominance during the assessment period. The growth is mainly attributed to the increasing initiatives taken by the U.S. Department of Health and Human Services in order to minimize the occurrence rate of infectious diseases
Europe is presumed to register a significant growth rate owing to the superior government spending like the National Health Service for the deployment of medical and pharmaceutical industries.
Asia Pacific is estimated to expand at a rapid pace owing to the increasing healthcare sector in the leading regions such as India and China. The Middle East and African region are also likely to expand at a steady pace due to extensive research and development activities coupled with the development in the healthcare infrastructure in this region.
Seborrheic Keratosis is a non-cancerous skin condition that is common in older adults. Skin growths on shoulders, back, abdomen, scalp, face, and chest may appear when suffering from the disease. The Seborrheic Keratosis Market is projected to reach USD 3.4 Billion by 2030 at 5.80% CAGR during the forecast period 2022-2030, asserts Market Research Future in an extensive study. Elevating consumer inclination towards aesthetics and growing awareness regarding physical appearance urge people to opt for the treatment of Seborrheic keratosis. Seborrheic keratosis can be easily treated with Cryosurgery where liquid nitrogen is used to prevent further growth. Also, in recent years, surgeries involving cosmetic procedures have entered the mainstream which spurs the growth of the market.
Notable improvements in treatment methods and the availability of diverse treatment options have contributed to the growth of the market. Other driving factors include extensive R&D efforts, surging prevalence of the disease, improving reimbursement scenario and availability of cost-effective treatment options. Conversely, the growth of the global Seborrheic Keratosis market might be hampered by post-surgery side effects, high costs associated with treatment which might limit market growth in price-sensitive and developing regions.
Competitive Landscape
The notable players in the global Seborrheic keratosis market include Quantumpm, Becton Dickinson and Company, Quanta Systems S.p.A., Aclaris Therapeutics, THOR Photomedicine, Syneron Medical Ltd., Cutera, Angiodynamics, Inc., Erchonia Corporation, Valeant, Lumenis, BioLight Technologies LLC, Alma Lasers, KAI Medical, IRIDEX Corp., Integra Miltex, Coherent, Inc., Apira Science Inc., Biolase Inc., and Theralase Inc.
Segmentation
The global Seborrheic keratosis market has been segmented based on type, diagnosis, treatment, and end user.
By type, the global Seborrheic keratosis market has been segmented into stucco keratosis, inverted follicular keratosis, reticulated Seborrheic keratosis or adenoid seborrheic keratosis, clonal seborrheic keratosis, seborrheic keratosis with squamous atypia, melanoacanthoma, dermatosis papulosa nigra, seborrheic keratosis, and irritated seborrheic keratosis.
The common seborrheic keratosis segment has been further segmented into basal cell papilloma and solid seborrheic keratosis.
The stucco keratosis segment has been further segmented into digitate seborrheic keratosis, serrated seborrheic keratosis, verrucous seborrheic keratosis, and hyperkeratotic seborrheic keratosis.
By diagnosis, the global seborrheic keratosis market has been segmented into skin biopsy and others.
By seborrheic keratosis treatment, the global seborrheic keratosis market has been segmented into surgical procedures, medication, medical procedures, seborrheic keratosis treatment and others. The surgical procedures segment has been further segmented into cryosurgery, electrocautery or electrosurgery, curettage, and others. The medical procedures segment has been further segmented into freezing, tissue scraping, laser therapy, and others.
By end user, the global the global seborrheic keratosis market has been segmented into hospital, clinics, diagnostic centers, pharmacies, and others.
Regional Analysis
The Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) are the key markets for seborrheic keratosis. The Americas dominate the global seborrheic keratosis market on account of surging awareness regarding the condition among the consumers and high expenditure on healthcare. The prevalence of seborrheic keratosis is also considerably high in the region which generates high demand for diagnosis and treatment. As per a report published in the Journal of Drugs in Dermatology in 2015, seborrheic keratosis affects more than 83 Mn Americans.
Europe commands the second largest position in the global seborrheic keratosis market. government support in the form of funding for R&D, the presence of private organizations who are engaged in extensive R&D and favorable reimbursement policies in the region drive the growth of the Europe Seborrheic keratosis market.
APAC is projected to be the fastest growing market for Seborrheic Keratosis. Presence of a vast patient pool, development of healthcare technology and the growing participation of market players in the region are stimulating the growth of the APAC market.
The MEA market is expected to account for the least share of the global market due to lack of medical facilities and affordability in the region. Moreover, the lack of awareness about the condition is also a market deterrent.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Insights
The chronic kidney disease market is expected to grow at a CAGR Of 5.40% during the forecast period 2022-2030. Rising occurrences of chronic diseases and the severity of kidney disease has increased the demand for an effective treatment option for the disease. Causes of chronic diseases are often indicated by diabetes, polycystic kidney disease, and high blood pressure among others.
Increasing R&D activities with regards to diagnostics and treatment are expected to offer market growth opportunities in the future. Moreover, developing economies offer a wider scope for growth during the forecast period and are expected to affect the market positively.
Increasing prevalence of kidney diseases and the increased number of biopsy procedures have resulted in high demand for new diagnostic and treatment options for such chronic diseases. The global chronic kidney disease market has become highly competitive with the increasing entry of new market players; this is expected to stimulate growth during the forecast period. Kidney disease symptoms are often negligible in the initial phases, and this type of disease is widely referred to as a "silent disease" as detection often happens when the diseases are progressed to a later stage. This has increased the need for appropriate diagnostic measures and is driving market growth.
Market Segmentation
MRFR's report segments the global chronic kidney disease market on the basis of diagnosis, treatment, indication, and end-user. By diagnosis, the market is segmented into blood test, urine test, imaging test, and kidney biopsy. By treatment, the market is segmented into drugs, dialysis, and kidney transplant. Drugs are further sub-segmented to include ace inhibitors, angiotensin-ii receptor blockers, calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.
By indication, the market is segmented into Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, and others. By end-user, The market is segmented into hospitals and clinics, diagnostic centers, and others. Globally, the market is divided into the Americas, Europe, Asia-Pacific & the Middle East and Africa.
Regional Analysis
The Americas and Europe are significant regional markets which have a similar growth pattern. The growth of medical devices, increasing awareness regarding kidney diseases and the rapid increase in occurrences of chronic diseases is expected to drive growth in these regions. Moreover, they display a robust demand for new treatment methods and options. Opportunities for these markets are being driven by the increasing emphasis on the development of new drugs. Supportive government legislature with regards to research & development and the availability of funds for research in these regions is expected to push the market in a forward direction.
Asia-Pacific is another important market due to its rapid growth. Prevalence of diseases such as diabetes and cardiovascular diseases are driving the demand for appropriate treatment options. The region has a rapidly improving healthcare sector which has improved infrastructure, and a wide pool of skilled healthcare professionals. Demand for advanced treatment technologies and other healthcare technology is expected to provide the market with opportunities for market expansion.
Key Players
MRFRs report includes the analysis of market players participating in the global chronic kidney diseases competitive landscape. Top market players include Hoffman-La Roche Ltd., Abbott, AstraZeneca Plc, Pfizer, Nova Biomedical, ARKRAY, OPTI Medical, and AbbVie to name a few.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Synopsis:
The Dietary Supplements in the Age of Personalized Nutrition Market is expected to reach USD 21,198.44 Million by 2030 at 6.70% CAGR during the forecast period 2022-2030.Increasing awareness regarding the necessity of nutrients in daily diet and rise in popularity of fitness programs are primarily propelling the expansion of the global dietary supplements in the age of personalized nutrition market. Increasing incorporation of technologically advanced research and manufacturing processes in the pharmaceutical and healthcare industry along with the high demand for personalized medication are also fueling the growth of the global dietary supplements in the age of personalized nutrition market. However, concerns regarding the side effects cause by these supplements are likely to act as restraining factors for the growth of the global dietary supplements in the age of personalized nutrition market during the forecast period.
Key Players:
The major players profiled by MRFR that are operating in the global dietary supplements in the age of personalized nutrition market are Nestlé Health Science, Danone Nutricia, Carlyle Group, Amway (Nutrilite), Archer Daniels Midland, Abbott Laboratories, Herbalife International, Amway, Danisco, Glanbia, Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Balchem Corporation, Natures Product Inc., Bactolac Pharmaceutical Inc. and others.
Regional Analysis:
The global dietary supplements in the age of personalized nutrition market has been geographically segmented into four major regions such as the Americas, Europe, Asia Pacific and the Middle East and Africa. Among these, the Americas command for the major share in the global dietary supplements in teh age of personalized nutrition market owing to the presence of leading manufacturers, high healthcare expenditure by the population of this region and utilization of advanced technology for the production of personalized drugs and supplements in this region. Increased research in the nutrition industry for the development of personalized dietary supplements by studying the DNA, dietary habits and other factors in an individual is majorly propelling the expansion of teh dietary supplements in the age of personalized nutrition market. Improving economic conditions, increasing geriatric population, government support for research and development in teh healthcare sector and rise in awareness regarding the health benefits of dietary supplements are boosting the dietary supplements in the age of personalized drugs market in the Asia Pacific region. Whereas, low penetration of proper healthcare services and lack of awareness among the population of the underdeveloped regions are leading to the slow growth of the dietary supplements in the age of personalized nutrition market in the Middle East and Africa market.
Market Segmentation:
The global dietary supplements in the age of personalized nutrition market has been segmented on the basis of product category, gender, application, dosage form and end user. Based on product category, the market has been segmented into vitamins, herbs & botanicals, sports supplements, dietary supplements ingredients, meal supplements, minerals and other. Based on application, the market has been segmented into lifestyle diseases, inherited diseases, genetic predispositions and others. Based on gender, the market has been segmented into female and male. The female segment has been sub-segmented into 55 + age group, 35-54 age group, 19-34 age group, and 0-18 age group. The male segment has also been sub-segmented into 55 + age group, 35-54 age group, 19-34 age group, and 0-18 age group. Based on dosage form, the market has been segmented into tablets, capsules, powder, liquids, soft gels and others. Based on end users, the market has been segmented into hospitals & clinics, home care, and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Diabetic Nephropathy Market was valued USD 2.48 billion in 2021 and is expected to reach USD 3.43 billion by 2030 at 6.20% CAGR during the forecast period 2022-2030. This can be attributed to rising cases of obesity and diabetes. Immense demand for diagnostic and imaging tests such as kidney biopsy, blood test, urine test, CT scan, and MRI scans can fuel the market demand. According to the World Health Organization, patients with chronic diseases touched a high of 35 million globally.
Diabetic nephropathy, known as diabetic kidney disease (DKD), is a kidney malady frequently found in patients with type 1 and type 2 diabetes. High prevalence of diabetes globally has culminated in diabetes co-morbidities. It can cause nephropathy which would require dialysis or a transplant. The global diabetic nephropathy market report by Market Research Future (MRFR) provides a quantitative and qualitative analysis by listing out trends, factors, and restraints with ample figures and statistics to back up the evidence.
Technological advances in diagnostic imaging and emphasis on early diagnosis for prevention of diseases are other drivers of the market. The expansion of the healthcare sector and availability of these tests at reputed hospitals and clinics can lend credibility to the trend. Rising number of clinical trials conducted to test the success of drugs for inhibiting the progress of DKD can provide new growth avenues. Angiotensin converting enzyme inhibitors (ACEi) have been known to have moderate success in clinical trials with placebo treatment in reducing the risk of death in patients with diabetes.
Competitive Outlook
Bayer AG, Siemens AG, AbbVie Inc., Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, Reata Pharmaceuticals, Inc., Pfizer Inc., Abbott, Merck & Co., Inc., General Electric Company, Novartis AG, Sanofi, and others are some of the noteworthy players in the global diabetic nephropathy market. Increased investments in research and development and drug discovery pertaining to chronic kidney disorders are the main focus of these players.
Segmentation Analysis
The global diabetic nephropathy market is segmented by diagnosis, treatment, indication, and end-user.
By diagnosis, it is segmented into imaging tests, urine tests, blood tests, renal function testing, and kidney biopsy. By treatment, it is segmented into kidney dialysis, medications, and transplant. By indication, it is segmented into diabetes 1 and diabetes 2. By end-user, it is segmented into research institutes, hospitals & clinics, diagnostic centers, and others.
Regional Analysis
Europe, the Americas, Asia Pacific (APAC), and the Middle East & Africa (MEA) are regions covered in the diabetic nephropathy market report.
The Americas are pegged to lead the global market till 2023 due to emphasis on diagnostic tests, constant monitoring of insulin levels, and large prevalence of chronic kidney disease (CKD). According to the U.S. National Chronic Kidney Disease, nearly 39 million Americans have CKD as of 2019. Large awareness levels can drive the regional market demand. This is exemplified with the American Diabetes Association for creating programs among diabetics for diabetes management.
The European region is deemed to be driven by kidney diagnosis tests for the geriatric populace combined with demand for diagnostic services. Germany is touted to be one of the biggest regions due to investment in new technologies and favorable reimbursement policies. High awareness of diabetes and its negligence which can cause kidney disorders is likely to drive the regional diabetic nephropathy market.
On the other hand, the APAC region is the third biggest globally and will sustain its ranking till the end of the forecast period. High prevalence of diabetes in Thailand, China, Japan, and India combined with chances of DKD in the region due to low patient awareness levels can work favorably for the market. The large geriatric population in these countries can also count as a viable factor driving the global diabetic nephropathy market growth.